A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
← catalyst calendarNCT06721013 · readout ≤ 651 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
68estimated
Sites
45
Countries
China, Denmark, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-30 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immune Thrombocytopenia (ITP)
Interventions
- Drug: Pirtobrutinib
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline Up to Week 4
Phase 1-Dose Limiting Toxicity (DLT) of Pirtobrutinib
measured Baseline Up to Week 4
Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Vital Signs: Blood Pressure, Pulse Rate, and Body Temperature
measured Baseline Up to Week 16
Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Clinical Lab Tests: Hematology, Clinical Chemistry, Urinalysis, Pregnancy, Hepatitis Serology and Cytomegalovirus (CMV)
measured Baseline Up to Week 16
Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Electrocardiograms (ECGs): ECG QT Interval
measured Baseline Up to Week 16
Phase 2-Efficacy of Pirtobrutinib Versus Placebo
measured Baseline Up to Week 24
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed